Uptrend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Jun 18 · inside the Ichimoku cloud · RSI 47 · MACD above its signal
None of the 29 investors followed here reported a position in ACOG in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACOG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 8.47 - 8.57 per share. | 31.8K | $270.80K |
| Sep 15, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 8.40 - 8.70 per share. | 123.9K | $1.06M |
| Aug 20, 2026 | Wills Robert JamesDirector | Purchase at price 9.62 per share. | 10K | $96.20K |
| Aug 2, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.92 - 8.00 per share. | 52.9K | $422.98K |
| Jul 23, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.90 per share. | 130 | $1.03K |
| Jul 22, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.80 - 7.83 per share. | 200.1K | $1.57M |
| Jun 25, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 6.40 - 6.50 per share. | 152.5K | $976.49K |
| Jun 14, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.91 - 5.99 per share. | 7.7K | $45.77K |
| Jun 9, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.98 - 5.99 per share. | 30.7K | $183.69K |
| Jun 4, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.83 per share. | 10.1K | $58.60K |
| May 28, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.73 - 5.90 per share. | 73.7K | $434.71K |
| May 20, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.70 - 5.89 per share. | 24.4K | $140.54K |
| May 18, 2026 | D'Angelo LaurenChief Operating Officer | Purchase at price 5.76 per share. | 3.5K | $20.16K |
| May 17, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.69 - 5.83 per share. | 34K | $196.01K |
| Apr 15, 2026 | Sensenig BethanyDirector | Stock Award(Grant) at price 0.00 per share. | 5.5K | — |
| Mar 29, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 4.99 - 5.08 per share. | 11.8K | $60.02K |
| Mar 25, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.28 - 5.59 per share. | 20.1K | $108.63K |
| Mar 18, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.71 - 5.75 per share. | 4.6K | $26.21K |
| Mar 15, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.78 per share. | 1.3K | $7.70K |
| Mar 12, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.75 - 5.85 per share. | 13.1K | $75.70K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.5 | 24.0 | -8.5 | 8.7 | 3.7 | 16.6 | 14.7 | 12.0 | -2.9 | -2.2 | +35.4% | ||
| 2025 | -2.9 | 5.1 | -15.8 | 9.1 | 69.0 | 0.0 | -2.4 | -8.9 | -21.6 | -4.9 | -2.7 | 8.0 | +10.4% |
| 2024 | -11.0 | −11.0% |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Buy / hold / sell counts